Rockwell Medical, Inc. revised earnings guidance for the year 2024. For the year, the company now expects Net Sales to be $90.0 million to $94.0 million compared to prior guidance of net sales of $84.0 million to $88.0 million, 13% to 18% increase over $79.8 million in net product sales for 2023. Gross profit of $13.0 million to $15.0 million compared to prior guidance of Gross Profit of $12.0 million to $14.0 million, 49% to 72% increase over $8.7 million in gross profit for 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -1.56% | +7.69% | 0.00% |
05-30 | Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer | CI |
05-14 | Transcript : Rockwell Medical, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 57.3M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.70% | 248B | |
-2.00% | 219B | |
+10.78% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- RMTI Stock
- News Rockwell Medical, Inc.
- Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024